Aguirre Lab - Pancreatic Cancer Research
  • Home
  • Research
  • People
    • Lab News
    • Photo Gallery
    • Join us!
  • Publications
  • Collaborate
  • Support Us
  • Contact Us
  • TargetKRAS
  • Financial Disclosures
​In the interest of full transparency, Dr. Aguirre reports the following financial disclosures:
 
Consulting:
Affini-T Therapeutics, Anji Pharmaceuticals, Arrakis Therapeutics, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Celex Oncology, Curie.Bio, Incyte, Kestrel Therapeutics, Merck & Co., Inc., Mirati Therapeutics, Nimbus Therapeutics, Oncorus, Inc., Pfizer, Plexium, Quanta Therapeutics, Reactive Biosciences, Revolution Medicines, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals, Taiho Pharmaceuticals, Third Rock Ventures, T-knife Therapeutics, and Ventus Therapeutics.

Equity: Riva Therapeutics
 
Research Funding: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Deerfield, Inc., Eli Lilly, Mirati Therapeutics, Novartis, Novo Ventures, Revolution Medicines, Syros Pharmaceuticals, Verastem Oncology.

Updated: March 31, 2025
 HOME | RESEARCH | PEOPLE | PUBLICATIONS | COLLABORATE | SUPPORT US | CONTACT

©2023 Aguirre Lab at Dana-Farber Cancer Institute
  • Home
  • Research
  • People
    • Lab News
    • Photo Gallery
    • Join us!
  • Publications
  • Collaborate
  • Support Us
  • Contact Us
  • TargetKRAS
  • Financial Disclosures